Scleroderma Joins Major Cross-Disease Autoimmune Research Initiative

The Foundation for the National Institutes of Health (FNIH) announced it is adding scleroderma to its Accelerating Medicines Partnership for Autoimmune and Immune-Mediated Diseases, known as AMP AIM, a research collaboration that already covers rheumatoid arthritis, lupus, Sjögren's disease, and psoriatic diseases. Scleroderma is a painful and often disabling autoimmune disease that causes the immune system to trigger excess scar tissue, or fibrosis, in the skin and sometimes in internal organs like the lungs, heart, and digestive tract. Current treatments are often not curative and can carry significant side effects, and because scleroderma is relatively rare, it has historically attracted less research funding and drug development attention than more common autoimmune conditions.

AMP AIM was launched in 2021 and is managed by the FNIH, which builds partnerships connecting scientists at the National Institutes of Health with life sciences companies, academic researchers, and patient advocacy groups. The program's core approach involves creating extremely detailed maps of the specific cells and molecules involved in each disease, then comparing those maps across conditions to identify which biological pathways are shared between diseases and which are unique. That cross-disease comparison is difficult to fund through traditional research grants, which typically focus on one disease at a time, making a collaborative model like AMP AIM particularly valuable for this kind of foundational work.

Two patient organizations, the National Scleroderma Foundation and the Scleroderma Research Foundation, are joining AMP AIM's four existing patient advocacy partners as part of this expansion. Program partners have committed more than $9 million in new funding specifically to support the scleroderma addition, on top of the $62 million already invested in the broader initiative since it launched. Including patient advocates directly in the research process is meant to help ensure that the scientific priorities researchers pursue actually reflect what matters most to people living with these diseases day to day.

For scleroderma patients, this expansion means the disease will now benefit from the same kind of detailed cellular and molecular mapping that has already been underway for rheumatoid arthritis, lupus, and other conditions in the program, potentially accelerating the identification of new drug targets and diagnostic tools. Because AMP AIM emphasizes comparing biology across multiple autoimmune diseases at once, researchers may also uncover connections between scleroderma and the program's other diseases that would be difficult to spot studying scleroderma in isolation. As with most large research infrastructure investments, the practical payoff, in the form of new diagnostics or treatments reaching patients, will likely take years to materialize, but investments like this lay the groundwork that future drug development depends on.